Eli Competitors
LLY Stock | USD 745.95 4.82 0.64% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Eli Lilly competition on your existing holdings.
Eli |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Eli Lilly's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Eli Lilly Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Eli Lilly and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Eli and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Eli Lilly does not affect the price movement of the other competitor.
0.42 | 0.51 | 0.67 | -0.18 | 0.4 | ALKS | ||
0.42 | -0.22 | 0.25 | -0.11 | 0.54 | IRWD | ||
0.51 | -0.22 | 0.71 | -0.32 | -0.24 | DCPH | ||
0.67 | 0.25 | 0.71 | -0.17 | -0.06 | EGRX | ||
-0.18 | -0.11 | -0.32 | -0.17 | 0.16 | NBIX | ||
0.4 | 0.54 | -0.24 | -0.06 | 0.16 | DVAX | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Eli Stock performing well and Eli Lilly Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Eli Lilly's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ALKS | 1.75 | (0.32) | 0.00 | (0.11) | 0.00 | 2.79 | 21.89 | |||
IRWD | 2.51 | (0.50) | 0.00 | (3.86) | 0.00 | 3.82 | 42.91 | |||
DCPH | 2.22 | (0.11) | (0.02) | 0.00 | 2.52 | 4.84 | 17.94 | |||
EGRX | 4.14 | 0.13 | 0.03 | 0.16 | 4.87 | 8.00 | 23.10 | |||
NBIX | 1.17 | (0.01) | (0.04) | 0.00 | 1.56 | 2.61 | 8.06 | |||
DVAX | 1.14 | (0.37) | 0.00 | (0.52) | 0.00 | 2.49 | 6.78 |
Cross Equities Net Income Analysis
Compare Eli Lilly and related stocks such as Alkermes Plc, Ironwood Pharmaceuticals, and Deciphera Pharmaceuticals Net Income Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALKS | (8.1 M) | (113.7 M) | 25 M | 17.6 M | (30.1 M) | (227.2 M) | (208.4 M) | (157.9 M) | (139.3 M) | (196.6 M) | (110.9 M) | (48.2 M) | (158.3 M) | 355.8 M | 373.5 M |
IRWD | (52.8 M) | (64.9 M) | (72.6 M) | (272.8 M) | (189.6 M) | (142.7 M) | (81.7 M) | (116.9 M) | (282.4 M) | (15.3 M) | 106.2 M | 528.4 M | 175.1 M | (1 B) | (952.1 M) |
DCPH | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (25.9 M) | (50.3 M) | (99.9 M) | (191.5 M) | (266.5 M) | (296.8 M) | (178.9 M) | (194.9 M) | (204.7 M) |
EGRX | (19.4 M) | (19.4 M) | (19.4 M) | (6 M) | (18 M) | 2.6 M | 81.5 M | 51.9 M | 31.9 M | 14.3 M | 12 M | (8.6 M) | 35.6 M | 41 M | 43 M |
NBIX | 5.9 M | 37.6 M | 5 M | (46.1 M) | (60.5 M) | (88.9 M) | (141.1 M) | (142.5 M) | 21.1 M | 37 M | 407.3 M | 89.6 M | 154.5 M | 249.7 M | 262.2 M |
DVAX | (26.7 M) | (48.6 M) | (69.9 M) | (66.7 M) | (90.7 M) | (106.8 M) | (112.4 M) | (95.2 M) | (158.9 M) | (151.4 M) | (91.8 M) | 76.7 M | 293.2 M | (6.4 M) | (6.7 M) |
Eli Lilly and related stocks such as Alkermes Plc, Ironwood Pharmaceuticals, and Deciphera Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Eli Lilly financial statement analysis. It represents the amount of money remaining after all of Eli Lilly and operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Eli Lilly Competitive Analysis
The better you understand Eli Lilly competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Eli Lilly's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Eli Lilly's competition over several years is one of the best ways to analyze its investment potential.Better Than Average | Worse Than Peers | View Performance Chart |
Eli Lilly Competition Performance Charts
Five steps to successful analysis of Eli Lilly Competition
Eli Lilly's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Eli Lilly in relation to its competition. Eli Lilly's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Eli Lilly in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Eli Lilly's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Eli Lilly, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Eli Lilly position
In addition to having Eli Lilly in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Dividend Beast Thematic Idea Now
Dividend Beast
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
View All Next | Launch |
Check out Eli Lilly Correlation with its peers. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Stocks Directory Find actively traded stocks across global markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.78 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.